Charles River Laboratories International, Inc. (CRL) continues to enhance its portfolio through targeted partnerships and acquisitions, poised to drive growth in the upcoming quarters. The company’s RMS (Research Models and Services) is witnessing broad-based growth in all geographic regions for small research models. Sound financial health also bodes well for the stock.  Meanwhile, volatilities in the biopharma industry remain a challenge for Charles River. Intense rivalry from other industry players adds ...